Search results for:
Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients
Nature publication reports that Ondine’s nasal antimicrobial photodynamic disinfection therapy suppresses SARS-CoV-2 in COVID-19 patients Vancouver, British Columbia, Canada - August 31, 2022 The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), [...]
Ondine completes enrollment for US Phase II nasal photodisinfection trial
Ondine Biomedical completes patient recruitment for US Phase II nasal photodisinfection trial Vancouver, British Columbia, Canada - August 8, 2022 Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s [...]
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Suppression of SARS-CoV-2 replication and infectivity in vaccinated individuals: a clinical study of Ondine Biomedical’s nasal photodisinfection carried out at the Clínica Universidad de Navarra, Spain Vancouver, British Columbia, Canada - July 19, 2022 Clínica Universidad de Navarra has completed a randomised controlled study of Ondine [...]
WHO calls for new innovations to tackle antimicrobial resistance crisis
WHO calls for new innovations to tackle antimicrobial resistance crisis Vancouver, British Columbia, Canada - July 6, 2022 Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has [...]
Photodisinfection effective against SARS-CoV-2
New study confirms that photodisinfection is rapidly effective against SARS-CoV-2 Vancouver, British Columbia, Canada - April 5, 2022 Ondine Biomedical (AIM: OBI) announces that independent research has confirmed previous results showing that Ondine Biomedical’s photodisinfection technology is highly effective against human clinical isolates of SARS-CoV-2. [...]
First patients treated in US Phase 2 trial
Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections Vancouver, British Columbia, Canada - February 7, 2022 Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare [...]
Photodisinfection could be game-changer in fight against resistance
Photodisinfection technology could be a game-changer in fight against antimicrobial resistance Vancouver, British Columbia, Canada - January, 2022 Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant infections. An analysis published in the Lancet found that 1.27 [...]
For Media Information
Simon Vane Percy
Amanda Bernard
